DWA
ELVN icon

Dorsey Wright & Associates’s Enliven Therapeutics ELVN Stock Holding History

Dorsey Wright & Associates’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,375
Closed -$28.1K – 295
2023
Q2 		$28.1K Buy
1,375
+138
+11% +$2.79K 0.01% 188
2023
Q1 		$27.1K Sell
1,237
-138
-10% -$2.81K 0.01% 172
2022
Q4 		$22.5K Buy
+1,375
New +$22K 0.01% 240

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Dorsey Wright & Associates's ELVN Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of Enliven Therapeutics (ELVN) in Q3 2023, closing a stake of 1,375 shares — an estimated $28.1K sold.

Dorsey Wright & Associates first reported a position in ELVN in Q4 2022 and held it in 3 quarters. The position peaked at $28.1K in Q2 2023. 61 funds tracked by Wall St. Rank hold ELVN as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining Enliven Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,375 Enliven Therapeutics shares in Q3 2023, an estimated $28.1K.
  • Dorsey Wright & Associates first reported a position in Enliven Therapeutics in Q4 2022 and held it in 3 quarters.
  • Dorsey Wright & Associates's Enliven Therapeutics position peaked at $28.1K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.